Global Point of Care
Global Point of Care
With cardiovascular diseases, such as coronary heart disease, cerebrovascular disease, rheumatic heart disease, heart attacks, and strokes claiming the lives of 17.9 million1 people each year, it’s no wonder heart health and heart health care are areas of concern within the population.
The need for healthcare innovations continues to grow and redefine the way we think about heart health. At the same time, the need for early detection is more important than ever, making point-of-care testing a catalyst for change in a more individualized approach to medicine.
There are a limited number of controlled clinical trials for POC lipid measurement; however of those that have been performed, nearly all affirm that POC tests are as accurate as conventional laboratory tests as it relates to stratifying patient’s risk of cardiovascular disease, such as in the 2009 Australian non-inferiority trial.2 The study was designed to show that POC testing was no worse than lab testing by a pre-specified minor amount. The results provided evidence that POC testing is non-inferior compared to conventional laboratory testing.
Today, POCT does not need to rely on established healthcare infrastructures. Even remote and underserved communities, though not without their challenges to immediate care, can still benefit from the convenience POCT offers. Rather, POCT can be viewed as a critical tool for making heart health assessment available to a broader population and for reducing some of the health disparities in cardiovascular disease.3
POC lipid testing is associated with improved statin therapy compliance. It is reported in the literature that typically 50% of patients stop using their lipid-lowering drug within the first 3 months and only 25% of the patients are compliant with the medication after 1 year.4,5
However, a study conducted by Bluml et al. showed that “routine lipid testing, and immediate face-to-face counselling achieved 90% compliance over a 24-month period.” 6
Multiple point-of-care tests may benefit heart health, from measuring cholesterol levels and blood pressure to conducting electrocardiograms (ECGs). The more tests there are, the more healthcare providers can tailor heart health monitoring to the needs of the patient.
Abbott recently developed a new cholesterol education site to help patients gain a better understanding of their Cholestech LDX™ test results and what to do to improve their cholesterol numbers. The site offers easy-to-understand explanations, user-friendly dietary and lifestyle tips, frequently asked questions, and links to more in-depth information from the American Heart Association website.
A Leader In Rapid Point-of-care Diagnostics.
©2024 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement
Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.
Abbott - A Leader in Rapid Point-of-Care Diagnostics.